Bipolar disorder (BP) is a multifactorial disease with complex inheritance. Inconsistencies of results of genetic studies are probably due in part to the heterogeneity of the disorder. We showed that a structural variant (cys23ser) of the serotonin 2C receptor gene (HTR2C) may be involved in 'early onset' phenotype of BP (EO-BP), supporting the notion that specific clinical indicators of BP, such as age at onset (AAO), may contribute to identify specific genetic vulnerability factors.
It has been recently shown that AAO does not have a normal distribution in BP, suggesting that it may be of value for distinguishing between various subgroups of BP. 1 Moreover, family studies have suggested that EO-BP may be associated with greater familial risk to relatives. 2 As a specific phenotype, EO-BP may be helpful to target vulnerability genes. In this study, we first investigated the distribution patterns of AAO by carrying out admixture analysis 3 in a large European sample of BP type 1 patients, 4 showing a mixture of 3 gaussian distributions of AAO in BP patients (Figure 1) .
In a second step, to assess whether AAO variation reflected the underlying genetic heterogeneity in BP, we examined the relationship of the HTR2C (cys23-ser) polymorphism (on chromosome Xq24) with EO-BP (cutoff of 16 years) in a subsample of BP patients previously reported by our group, 5 including 625 BP (of whom 66 were EO-BP) and 829 controls, recruited in eight collaborative centers (Athens, Bonn, Brussels, Edinburgh, Jerusalem, Milan, Sofia, Zagreb). All subjects were assessed by using criteria identified at standard diagnostic interviews, according to the DSM-IV. 4, 6 AAO was defined on the basis of self-report as the age at first episode of mania or depression that met diagnostic DSM-IV criteria. 6 Local ethical committees approved the study, and written informed consent was obtained from all subjects.
The method for genotyping the HTR2C (cys23ser) polymorphism is detailed in our previous report. 5, 7 We performed logistic regression analyses to evaluate the effect of the 'diagnosis status' (EO-BP, BP with AAO > 16 years and control subjects) and the 'center' as predictors of the dependent variable (alleles/Ser23 carrier status), permitting to determine the significance of the diagnosis, controlled for the potential confounding effect of center. A significant association emerged with an excess of HTR2C Ser23 allele (23.8%) in EO-BP patients compared to controls (14.4%) (P = 0.004; OR = 2.1, CI (1.3; 3.4)) and BP with AAO > 16 (16.5%) (P = 0.039; OR = 1.7, CI (1.02; 2.9)). No difference was shown between BP group with AAO > 16 years and controls. We tested a 'dominant' role for Ser23 allele (because of the suggestive findings from our previous analyses 5 ), considering the response variable as 'Ser23 allele carrier status' (Ser23-Ser23 homozygous females, Ser23 hemizygous males and Cys23-Ser23 heterozygous females versus Cys23-Cys23 homozygous females and Cys23 hemizygous males). A significant excess of Ser23 allele carrier status emerged: 34.8% in EO-BP, 20.1% in control subjects (P = 0.002, OR = 2.4 (1.4-4.2) ) and 23.8 % in BP > 16 years group (P = 0.028, OR = 1.9 (1.07-3.37)).
These findings suggest that (1) EO may be a phenotypical marker distinguishing various subtypes of BP, supporting recent evidence that AAO may be a key indicator for the definition of homogeneous subtypes of BP 8 ; (2) specific genetic vulnerability factors such as the Ser23 allele may be involved in EO-BP or be in linkage disequilibrium with a causative polymorphism in the vicinity. Age-specific variations in neurotransmitters and other developmental differences may be associated with different phenotypic manifestations of BP across the age span. AAO subgroups of BP patients may be related to different genetic vulnerability factors or the same genetic mechanism differently expressed in various environments at developmental steps. The Ser23 allele may be involved as a specific susceptibility gene in EO-BP phenotype or act as a modifier factor, contributing to influence AAO of the BP phenotype. Because this study is limited to a single genetic variant, the possibility of a false-positive finding cannot be excluded. Genotyping more markers and using a haplotype-based approach, family-based association methods and samples from prospective studies of first episode patients are needed to replicate and further investigate the role of HTR2C in the genetics of EO-BP. While it has been suggested that EO in BP is the most severe form, associated with poor prognosis, 8 if replicated, the HTR2C Ser23 variant, as a risk factor of EO-BP, could help to detect EO-BP and better define a therapeutic strategy. 
